Shares of Merck & Co., Inc. (NYSE:MRK) ended Friday session in green amid volatile trading. The shares closed up +0.39 points or 0.67% at $58.82 with 11.32 million shares getting traded. Post opening the session at $58.69, the shares hit an intraday low of $58.61 and an intraday high of $59.26 and the price vacillated in this range throughout the day. The company has a market cap of $164.26 billion and the numbers of outstanding shares have been calculated to be 2.77 billion shares.
Merck & Co., Inc. (MRK) recently declared the publication of research conducted by Merck scientists on the discovery and development of verubecestat, an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), for the potential treatment of Alzheimer’s disease (AD). The research was published online in the most recent edition of the peer-reviewed journal Science Translational Medicine and includes results from the Phase 1 clinical trials in healthy volunteers and people with AD. The efficacy and safety of verubecestat is presently being evaluated in two pivotal Phase 3 clinical trials, EPOCH and APECS, for the treatment of mild-to-moderate AD and prodromal AD, respectively.
Shares of AbbVie Inc (NYSE:ABBV) ended Friday session in green amid volatile trading. The shares closed up +0.15 points or 0.27% at $56.04 with 11.19 million shares getting traded. Post opening the session at $56.07, the shares hit an intraday low of $55.87 and an intraday high of $56.87 and the price vacillated in this range throughout the day. The company has a market cap of $91.81 billion and the numbers of outstanding shares have been calculated to be 1.63 billion shares.
AbbVie Inc (ABBV) recently declared that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to veliparib, an oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, being investigated in combination with chemotherapies, such as carboplatin and paclitaxel, or radiation for the treatment of advanced squamous non-small cell lung cancer (NSCLC).
PARP is a naturally-occurring enzyme in the body that repairs damage to DNA in cells. While this repair is a useful process to maintain the integrity of healthy cells, the same process may also assist repair DNA in cancer cells, causing them to survive. Researchers are investigating whether veliparib, a PARP inhibitor, in combination with DNA damaging therapies, such as chemotherapy or radiation, may lessen the repair of DNA damage in cancer cells, eventually causing some cells to die.